target
anim
safeti
protocol
use
examin
advers
event
male
femal
fischer
rat
treat
increas
dose
subcutan
implant
lipid
suspens
buprenorphin
singl
inject
mgkg
afford
clinic
signific
blood
level
drug
day
chemistri
hematolog
coagul
urinalysi
valu
excess
dose
druglipid
suspens
within
normal
limit
histopatholog
find
unremark
skin
underli
tissu
surround
drug
inject
unremark
approxim
cohort
rat
given
excess
dose
mgkg
display
nausearel
behavior
consist
intermitt
limit
excess
groom
selfgnaw
result
confirm
safeti
cholesteroltriglycerid
carrier
system
subcutan
drug
deliveri
buprenorphin
laboratori
anim
demonstr
util
lipidbas
carrier
scaffold
subcutan
longact
drug
therapi
challeng
provid
longact
drug
therapi
laboratori
anim
manag
ad
drug
feed
water
suppli
util
method
decreas
mixtur
may
releas
inadvert
environ
drug
regul
control
substanc
feedbas
drug
also
may
limit
postsurg
applic
pain
suppress
appetit
altern
approach
focus
longact
drug
implant
made
combin
drug
biodegrad
envelop
compos
lipid
polym
polym
studi
drug
carrier
neurooncolog
side
effect
gener
modest
local
polym
implant
neural
tissu
less
known
biodegrad
polym
subcutan
sc
deliveri
chemotherapi
moder
sever
inflammatori
reaction
report
sc
implant
polymeropi
construct
investig
properti
lipidbas
deliveri
vehicl
cholesterol
triglycerid
phospholipid
wide
use
drugcarri
kent
describ
implant
cholesterol
matrix
deliv
larg
molecul
insulin
growth
hormon
grant
cowork
demonstr
phospholipidmorphin
liposom
prolong
activ
greater
safeti
mice
free
drug
liposom
strategi
refin
deliveri
sever
opiat
pontani
misra
describ
cholesteroltriglycerid
matrix
longterm
deliveri
drug
treat
chronic
pain
opiat
addict
cholesteroltriglycerid
vehicl
appear
provid
promis
carrier
examin
deliveri
antibiot
antiinflammatori
drug
analges
surgic
treat
anim
investig
safeti
system
chose
journal
veterinari
medicin
buprenorphin
model
drug
high
therapeut
index
frontlin
analges
anim
present
report
describ
bioequival
studi
demonstr
mgkg
dose
lipidbuprenorphin
suspens
provid
blood
concentr
drug
greater
ngml
day
concentr
associ
clinic
effect
analgesia
mice
dog
human
standard
analgesiometr
test
confirm
efficaci
intend
mgkg
dose
safeti
studi
use
target
anim
safeti
ta
trial
format
surgic
treat
male
femal
rat
inject
multipl
overdos
drug
suspens
monitor
advers
event
ae
trial
includ
clinic
test
histopatholog
studi
clinic
observ
result
describ
present
report
taken
togeth
previou
report
safeti
lipidbuprenorphin
suspens
mice
provid
evid
sc
drug
implant
use
lipid
envelop
increas
option
longterm
drug
therapi
rat
preliminari
account
research
publish
studi
approv
john
hopkin
institut
anim
care
use
committe
protocol
compli
nation
institut
health
guid
care
use
laboratori
anim
requir
associ
assess
accredit
laboratori
anim
care
intern
program
guidelin
ta
studi
specifi
minimum
number
three
anim
per
group
four
rat
use
ta
studi
account
potenti
morbid
jugular
vein
phlebotomi
fischer
rat
week
old
male
g
femal
g
obtain
tacon
farm
hudson
ny
hous
environment
control
room
maintain
temperatur
c
monthli
health
surveil
conduct
soiledbed
sentinel
system
sentinel
rat
consid
neg
pneumonia
viru
mice
reoviru
sendai
viru
lymphocyt
choriomening
viru
rat
coronaviru
sialodacryoaden
viru
rat
parvoviru
kilham
rat
viru
toolan
parvoviru
rat
theiloviru
ciliaassoci
respiratori
bacillu
pneumocysti
carinii
mycoplasma
pulmoni
pinworm
throughout
studi
facil
maintain
rel
humid
light
cycl
light
pm
anim
ear
tag
group
hous
per
cage
quarantin
acclim
period
base
sex
rat
quarantin
acclim
six
day
prior
dose
diseaserel
sign
note
quarantineacclim
period
prior
place
test
clinic
veterinarian
approv
anim
studi
use
rat
appear
normal
prior
dose
anim
assign
two
ta
trial
random
bodi
weight
four
group
per
trial
male
femal
rat
use
random
number
gener
excel
microsoft
corp
redmond
wa
weight
anim
within
mean
weight
group
alloc
dose
rat
bioequival
efficaci
ta
trial
individu
hous
ventil
microisol
cage
throughout
studi
cage
chang
daili
reduc
redos
coprophagi
studi
use
soft
fiber
bed
carefresh
natur
bed
ferndal
wa
hous
rat
anim
provid
ad
libitum
access
drink
water
baltimor
citi
water
system
baltimor
md
dispos
water
bottl
anim
provid
ad
libitum
access
harlan
teklad
certifi
global
rodent
diet
harlan
teklad
indianapoli
rat
provid
enrich
devic
polycarbon
red
tube
bio
servic
uden
netherland
design
intend
label
dose
mgkg
provid
day
clinic
signific
blood
level
drug
establish
bioequival
trial
efficaci
studi
describ
use
male
femal
rat
singleand
repeatdos
ta
trial
perform
use
excess
amount
intend
dose
safeti
trial
lowest
dose
drug
test
twofold
greater
intend
label
dose
mgkg
singledos
phase
trial
group
rat
male
femal
dose
surgeri
describ
vehicl
control
mgkg
drug
suspens
buprenorphin
day
volum
vehicl
control
dose
ml
respect
shown
tabl
blood
urin
sampl
collect
day
day
anim
euthan
blood
urin
collect
repeatdos
trial
group
rat
male
femal
dose
surgeri
vehicl
control
drug
suspens
contain
mgkg
buprenorphin
day
follow
anesthesia
day
surgeri
repeat
day
blood
urin
sampl
collect
day
blood
urin
histopatholog
studi
conduct
tissu
collect
follow
euthanasia
day
tabl
surgic
procedur
perform
mimic
implant
implant
pump
telemetri
devic
rat
anesthet
isofluran
ga
approxim
oxygen
flow
rate
procedur
durat
anesthesia
exposur
approxim
minut
follow
induct
anesthesia
scapular
surfac
shoulder
blade
shave
wash
ethanol
coat
betadin
anim
transfer
clean
procedur
area
assess
ensur
deep
surgic
plane
anesthesia
use
toe
pinch
method
deep
anesthesia
verifi
breath
rate
capillari
fill
rate
document
clean
steril
forcep
use
gentli
grasp
skin
clean
steril
scissor
use
make
mm
incis
skin
bone
muscl
penetr
clean
steril
scissor
use
separ
skin
cm
rostral
distal
cm
later
subcuti
creat
subcutan
pocket
approxim
cm
incis
appos
stapl
use
mm
kent
scientif
torrington
ct
drug
suspens
consist
buprenorphin
cholesterol
glycerol
tristear
suspend
mediumchain
triglycerid
oil
ul
trade
name
animalges
mice
control
drug
suspens
suppli
animalges
lab
millersvil
md
limit
stress
associ
constrain
consciou
anim
sc
inject
rat
inject
design
dose
test
articl
buprenorphinefre
control
suspens
follow
surgeri
recov
anesthesia
singledos
trial
repeatdos
trial
rat
inject
drug
follow
surgeri
anesthesia
day
anesthesia
day
dose
administ
sc
middors
area
cm
rostral
surgic
incis
use
g
needl
bd
franklin
nj
attach
ml
bd
tuberculin
syring
follow
dose
administr
anim
transfer
clean
cage
heat
pad
recov
rat
regain
conscious
demonstr
normal
movement
absenc
sign
distress
return
home
cage
male
femal
rat
provid
singl
dose
drug
sampl
time
interv
hour
day
measur
blood
concentr
buprenorphin
rat
blood
sampl
obtain
technicianrestrain
unanesthet
anim
jugular
vein
phlebotomi
one
ml
dispos
syring
needl
use
collect
approxim
ml
blood
sampl
immedi
transfer
bd
tube
contain
dipotassium
edta
sampl
store
ice
approxim
hour
centrifug
collect
plasma
plasma
store
c
thaw
analysi
buprenorphin
plasma
concentr
measur
mcwhorter
school
pharmaci
samford
univers
birmingham
al
use
shimadzu
columbia
md
mass
spec
appli
biosystem
qtrap
carlsbad
ca
assay
requir
ml
plasma
sensit
assay
ngml
mean
concentrationtim
data
use
pharmacokinet
analysi
noncompartmentalanalys
modul
phoenix
winnonlin
version
princeton
nj
use
assess
area
curv
auc
maximum
plasma
concentr
max
time
cmax
realiz
max
max
max
observ
valu
auc
calcul
loglinear
trapezoid
rule
end
sampl
collect
auclast
efficaci
studi
conduct
femal
rat
two
dose
level
mgkg
rat
inject
vehicl
mgkg
dose
drug
test
tail
flick
respons
use
c
water
bath
test
conduct
femal
veterinarian
blind
treatment
group
femal
rat
use
mu
opioid
agonist
morphin
appear
less
sensit
femal
male
rat
rat
inject
drug
vehicl
day
examin
day
monitor
tail
flick
reaction
time
rat
hous
per
cage
cage
chang
daili
cours
studi
anim
observ
cage
level
daili
singl
observ
prior
morbid
mortal
sign
pain
stress
abnorm
breath
tremor
ocular
discharg
facial
sign
squint
eye
close
postur
movement
overal
appear
includ
condit
hair
coat
groom
incis
site
examin
time
bleed
swell
sign
infect
pica
expect
method
measur
kaolin
intak
use
anim
receiv
handson
detail
clinic
observ
daili
singl
observ
pm
abnorm
clinic
sign
ocular
discharg
motor
activ
sign
pain
distress
incis
site
examin
time
bleed
swell
sign
infect
bodi
surfac
inspect
skin
lesion
process
use
observ
record
nausearel
behavior
publish
briefli
observ
note
comment
report
form
hair
loss
presenc
lesion
evid
excess
groom
selfgnaw
behavior
grade
amount
hair
loss
degre
bite
consid
report
hair
loss
lesion
paw
sign
nausearel
behavior
record
number
rat
sex
experiment
group
show
sign
observ
period
observ
blind
treatment
group
approxim
data
point
record
two
trial
addit
observ
could
add
comment
chart
two
male
observ
certifi
aala
lab
anim
technologist
technician
weight
individu
anim
taken
random
prior
studi
start
midpoint
day
day
endpoint
day
day
safeti
trial
observ
blind
dose
patholog
blood
urin
sampl
collect
midand
endpoint
ta
trial
blood
collect
morn
via
jugular
vein
punctur
approxim
ml
blood
collect
midpoint
clinic
patholog
studi
midpoint
sampl
transfer
collect
tube
contain
dipotassium
edta
approxim
ml
endpoint
sampl
transfer
collect
tube
contain
dipotassium
edta
ml
transfer
collect
tube
contain
sodium
citrat
coagul
factor
measur
sampl
refriger
analys
hematolog
examin
includ
red
blood
cell
rbc
count
hemoglobin
hematocrit
mean
corpuscular
volum
mean
corpuscular
hemoglobin
mean
corpuscular
hemoglobin
concentr
platelet
count
white
blood
cell
wbc
count
differenti
blood
cell
count
blood
smear
clinic
chemistri
test
includ
glucos
urea
nitrogen
creatinin
total
protein
albumin
globulin
calcul
total
cholesterol
alanin
aminotransferas
alkalin
phosphatas
aspart
aminotransferas
calcium
sodium
potassium
chlorid
phosphat
two
ta
trial
coagul
factor
measur
prothrombin
time
activ
partial
thromboplastin
time
fibrinogen
amount
blood
need
coagul
factor
analyz
endpoint
day
express
urin
sampl
collect
afternoon
clean
surfac
pipet
steril
eppendorf
tube
urin
dip
stick
bayer
multistix
sg
reagent
strip
romeovil
il
read
manual
test
measur
ph
appear
color
protein
glucos
bilirubin
blood
final
collect
blood
urin
specimen
endpoint
day
anim
human
euthan
use
co
inhal
follow
thoracotomi
death
confirm
cessat
heart
rate
comprehens
necropsi
perform
anim
lung
examin
weigh
inflat
formalin
ensur
proper
fixat
tissu
place
individu
label
contain
contain
neutralbuff
formalin
except
test
male
eye
optic
nerv
preserv
modifi
davidson
fix
short
term
studi
test
eye
optic
nerv
transfer
modifi
davidson
solut
ethanol
day
follow
collect
transfer
perform
document
histolog
lab
contain
label
studi
number
date
group
number
anim
number
organ
weight
includ
adren
brain
epididymi
heart
kidney
liver
lung
ovari
spleen
test
thyroid
parathyroid
uteru
cervix
accord
ta
protocol
histopatholog
studi
perform
vehicl
control
anim
anim
given
highest
dose
drug
singleand
repeatdos
trial
tabl
unless
signific
patholog
observ
highest
dose
slide
two
lower
dose
examin
slide
vehicl
control
anim
dose
longterm
studi
examin
thirtythre
tissu
harvest
histopatholog
examin
organ
includ
dorsal
skin
surround
inject
site
adren
gland
larg
intestin
colon
small
intestin
jejunum
ileum
duodenum
larg
intestin
cecum
liver
bone
bone
marrow
femur
urinari
bladder
lung
spinal
cord
spine
brain
cerebrum
midbrain
cerebellum
medullapon
lymph
node
includ
submandibular
superfici
cervic
collect
salivari
gland
neck
mesenter
pancreaticoduoden
collect
mesenteri
pancrea
spleen
epididymi
male
mammari
gland
femal
stomach
eye
optic
nerv
ovari
femal
ventral
skin
gall
bladder
pancrea
heart
parathyroid
gland
parathyroid
gland
evalu
present
plane
section
thyroid
gland
thyroid
parathyroid
testi
male
kidney
skelet
muscl
bicep
femori
comprehens
statist
analysi
mean
standard
deviat
conduct
group
mean
bodi
weight
data
compar
treat
group
control
group
sex
use
oneway
analysi
varianc
anova
addit
zeroinfl
poisson
regress
conduct
estim
dose
sex
differ
time
pica
behavior
zeroinfl
poisson
regress
model
provid
robust
estim
hypothesi
test
count
data
predomin
zero
statist
analys
mean
standard
deviat
conduct
organ
weight
clinic
patholog
data
compar
treat
group
control
group
use
oneway
analysi
varianc
anova
addit
dunnett
test
use
control
versu
treat
group
comparison
studi
bioavail
buprenorphin
pharmacokinet
profil
male
femal
rat
defin
time
point
follow
singl
sc
inject
test
articl
examin
shown
tabl
singl
dose
mgkg
provid
least
day
clinic
signific
drug
concentr
defin
greater
ngml
plasma
buprenorphin
singl
femal
signific
concentr
plasma
buprenorphin
day
tabl
also
show
concentr
blood
present
rat
dose
mgkg
drug
male
femal
rat
clinic
relev
plasma
concentr
buprenorphin
throughout
day
singledos
repeatdos
trial
lowest
dose
evalu
advers
effect
mgkg
tabl
estim
valu
auc
max
max
given
tabl
b
max
femal
rat
dose
group
hour
max
male
rat
mgkg
dose
group
move
hour
base
slightli
greater
mean
blood
concentr
buprenorphin
day
max
valu
mgkg
group
ngml
male
femal
rat
respect
estim
max
valu
male
femal
rat
mgkg
dose
group
greater
male
rat
greater
femal
data
tabl
show
extend
releas
prepar
buprenorphin
provid
signific
analges
effect
mgkg
dose
rat
surviv
schedul
termin
date
trial
rat
dose
test
articl
averag
appear
slightli
slower
movement
score
compar
vehicl
control
rat
studi
day
approxim
hour
dose
administr
minor
wound
front
paw
wrist
associ
excess
groom
selfgnaw
note
drug
treat
anim
trial
excess
groom
selfgnaw
behavior
observ
morn
observ
period
given
anim
behavior
infer
absenc
hair
presenc
wound
paw
observ
note
find
comment
anim
chart
amount
hair
loss
degre
bite
grade
evid
open
wound
nausearel
sign
seen
pm
observ
cycl
anim
physic
handl
examin
surgeri
site
monitor
entir
skin
surfac
lesion
sign
nausearel
behavior
first
note
one
male
anim
day
analges
inject
mgkg
singledos
trial
tabl
singl
male
rat
mgkg
dose
group
exhibit
behavior
day
day
rat
mgkg
dose
group
show
increas
incid
time
behavior
highest
cumul
number
anim
exhibit
sign
day
day
day
highest
dose
group
mgkg
exhibit
delay
onset
lower
incid
behavior
compar
mgkg
group
day
similar
pattern
seen
repeatdos
trial
overal
day
selflick
paw
bite
seen
anim
drug
treat
group
beta
se
behavior
consist
focus
forepaw
male
femal
rat
exhibit
similar
rate
type
behavior
beta
se
three
anim
vehicl
control
group
repeatdos
trial
exhibit
behavior
sign
pain
distress
note
anim
male
one
femal
rat
treat
mgkg
buprenorphin
lost
weight
day
singledos
trial
tabl
two
male
rat
treat
mgkg
buprenorphin
continu
lose
weight
cours
studi
two
gain
weight
day
overal
weight
gain
cours
studi
femal
rat
treat
mgkg
buprenorphin
lost
weight
day
two
overal
weight
loss
cours
studi
male
rat
treat
mgkg
buprenorphin
lost
weight
day
femal
treat
dosag
gain
weight
altern
femal
rat
treat
mgkg
buprenorphin
lost
weight
day
male
treat
dosag
gain
weight
shown
tabl
similar
pattern
weight
chang
seen
repeatdos
trial
male
rat
mgkg
dose
group
treat
dose
day
gain
least
amount
weight
day
femal
rat
mgkg
repeatdos
group
show
least
weight
gain
overal
signific
chang
bodi
weight
vehicl
control
drug
treat
rat
signific
chang
organ
weight
measur
increas
dose
drug
either
male
femal
rat
singledos
trial
organ
weight
liver
male
mgkg
mgkg
group
repeatdos
trial
show
signific
post
hoc
differ
compar
vehicl
control
group
treatmentrel
effect
seen
upon
microscop
examin
tissu
organ
weight
measur
brain
heart
kidney
spleen
thyroid
remain
essenti
unchang
increas
dose
drug
also
effect
weight
epididymi
test
male
uteru
femal
averag
weight
adren
gland
male
rat
increas
control
valu
g
highest
dose
group
chang
seen
femal
rat
averag
liver
weight
decreas
drug
treat
male
femal
rat
signific
weight
chang
organ
liver
rat
longterm
studi
test
express
urin
singledos
trial
detect
urin
protein
rat
day
day
respect
repeatdos
trial
protein
detect
anim
day
day
sampl
find
correl
dose
group
sex
singledos
trial
trace
amount
blood
detect
rat
day
day
respect
repeatdos
trial
blood
detect
rat
day
rat
day
trial
valu
vari
trace
moder
level
find
correl
sex
dose
group
test
glucos
bilirubin
neg
sampl
appear
ph
color
normal
sampl
trial
coagul
factor
test
perform
blood
day
singledos
trial
day
repeatdos
trial
prothrombin
time
activ
partial
thromboplastin
time
fibrinogen
level
normal
dose
group
male
femal
rat
averag
differ
valu
control
drug
group
note
hematolog
valu
clinic
chemistri
paramet
one
ta
trial
paramet
examin
determin
whether
chang
drug
treatment
vari
increas
increas
dose
male
femal
rat
numer
case
differ
control
valu
valu
anim
seen
mgkg
dose
level
seen
mgkg
dose
level
differ
note
control
anim
receiv
drugchalleng
chang
valu
remain
within
normal
rang
equal
valu
control
group
rbc
valu
consist
decreas
day
day
endpoint
collect
compar
day
day
midpoint
valu
group
chang
attribut
blood
loss
due
previou
blood
collect
slight
increas
wbc
count
phlebotomi
increas
observ
mous
phlebotomi
among
rbc
indic
signific
differ
control
group
anim
mgkg
dose
group
indic
differ
note
per
group
sex
random
evid
leucopenia
cytosi
absolut
valu
nucleat
wbc
unremark
includ
neutrophil
eosinophil
basophil
alanin
aminotransferas
aspart
aminotransferas
sensit
yet
modestli
specif
indic
hepatocyt
damag
elev
serum
plasma
enzym
activ
expect
druginduc
hepatotox
present
studi
enzym
level
drug
group
close
resembl
control
valu
even
highest
level
drug
test
sever
group
modestli
decreas
serum
alkalin
phosphatas
alp
alter
physiolog
patholog
chang
variou
tissu
includ
kidney
hepatobiliari
intestin
bone
present
studi
alp
valu
decreas
significantli
increas
dose
challeng
sustain
decreas
level
alp
associ
loss
appetit
fast
cholesterol
bun
creatinin
calcium
level
show
small
inconsist
signific
chang
drug
control
group
valu
drug
control
group
remain
within
establish
laboratori
normal
valu
electrolyt
level
unremark
chlorid
sodium
potassium
shown
tabl
total
protein
level
averag
decreas
highest
dose
group
compar
control
decreas
signific
mgkg
dose
group
decreas
total
protein
level
appear
entir
relat
decreas
albumin
level
increas
drug
exposur
tabl
primari
factor
affect
albumin
synthesi
includ
protein
amino
acid
nutrit
colloid
osmot
pressur
action
certain
hormon
diseas
state
fast
proteindefici
diet
caus
decreas
albumin
synthesi
long
defici
state
maintain
longterm
studi
bun
valu
decreas
mgkg
group
compar
mgkg
group
vehicl
control
mgdl
respect
histopatholog
singledos
studi
report
macroscop
observ
thymu
one
male
rat
control
dose
group
present
discolor
red
microscop
present
hemorrhag
consid
incident
find
possibl
relat
termin
cardiocentesi
microscop
chang
observ
repeatdos
trial
macroscop
observ
necropsi
includ
redden
mandibular
lymph
node
one
vehicl
control
femal
one
male
rat
treat
mgkg
subcutan
hemorrhag
inject
site
one
femal
two
male
treat
mgkg
fluid
fill
uteru
one
femal
treat
mgkg
thicken
skin
later
site
inject
one
femal
treat
mgkg
mm
nodul
median
lobe
liver
one
femal
mgkg
dose
group
although
organ
weight
liver
male
mgkg
mgkg
group
repeatdos
trial
show
signific
post
hoc
differ
compar
vehicl
control
group
treatmentrel
effect
seen
upon
microscop
examin
tissu
inflammatori
chang
granulocyt
infiltr
mix
cell
infiltr
hemorrhag
commonli
seen
increas
sever
near
dorsal
skin
inject
site
rat
mgkg
dose
group
similar
chang
seen
vehicl
control
group
microscop
chang
observ
object
studi
evalu
safeti
lipid
suspens
buprenorphin
deliveri
postprocedur
pain
relief
rat
blood
level
measur
demonstr
singl
mgkg
sc
dose
cholesteroltriglycerid
buprenorphin
suspens
provid
signific
blood
concentr
drug
least
two
day
tabl
follow
declin
mean
plasma
concentr
drug
day
singl
femal
rat
dose
group
elev
blood
concentr
day
secondari
peak
may
attribut
redos
coprophagi
studi
shown
initi
dose
buprenorphin
excret
unmetabol
within
one
week
max
intend
dose
mgkg
hour
male
femal
rat
estim
auc
femal
rat
given
singl
mgkg
valu
male
rat
given
dose
slightli
greater
male
given
mgkg
dose
tabl
b
comparison
paramet
two
dose
group
difficult
littl
known
pharmacokinet
sc
lipid
drug
deliveri
system
blood
collect
day
rat
mgkg
test
group
limit
potenti
morbid
associ
jugular
phlebotomi
efficaci
studi
use
potenti
pain
stimulu
confirm
mgkg
dose
male
femal
rat
provid
analgesia
least
three
day
tabl
review
specif
test
demonstr
thermal
sensit
test
provid
good
predictor
clinic
efficaci
human
high
thermal
latenc
measur
day
mgkg
dose
level
somewhat
surpris
bioequival
test
separ
cohort
male
femal
rat
dose
level
tabl
demonstr
mean
blood
level
buprenorphin
drop
mgml
day
yet
result
consist
studi
extend
releas
buprenorphin
depot
human
volunt
show
blood
level
decreas
drug
mgml
end
first
week
signific
clinic
effect
maintain
almost
week
buprenorphin
metabolit
norbuprenorphin
rapidli
convert
glucuronid
conjug
rat
conjug
biolog
activ
may
rel
undetect
standard
lcm
assay
standard
safeti
trial
format
present
studi
use
excess
dose
challeng
monitor
advers
effect
might
occur
real
world
situat
anim
given
repeat
dose
drug
morbid
could
enhanc
drug
toxic
opiat
class
associ
respiratori
defici
studi
rat
demonstr
compar
morphin
fentanyl
methadon
ceil
effect
action
buprenorphin
present
studi
demonstr
prolong
buprenorphin
therapi
lipid
envelop
safe
toler
young
adult
rat
effect
speci
older
anim
transgen
rat
remain
unknown
decreas
efficaci
toler
hyperalgesia
attribut
opiat
includ
buprenorphin
studi
illustr
complex
associ
experiment
design
chronic
drug
therapi
hyperalgesia
signific
sign
locomotor
activ
hyperalgesia
observ
studi
describ
interest
question
concern
clinic
signific
hyperalgesia
appear
moot
studi
chronic
buprenorphin
therapi
use
transderm
skin
patch
case
report
hyperalges
sign
minim
rat
human
cowan
et
al
describ
first
report
buprenorphineinduc
nausea
rat
increas
stereotyp
lick
bite
movement
mitchel
cowork
demonstr
associ
nausea
pica
spin
rat
induc
motion
sick
yamamoto
et
al
demonstr
radiat
sick
induc
pica
takeda
cowork
confirm
associ
treat
rat
opiat
inhibitor
prevent
nausea
de
jongh
et
al
demonstr
pica
rat
adapt
respons
nausea
drug
block
mu
receptor
methylnaltrexon
use
block
emet
effect
opiat
human
pica
rat
two
ta
trial
mgkg
dose
conduct
soft
bed
reduc
risk
intestin
blockag
allow
prospect
determin
rate
emet
behavior
shown
tabl
observ
cumul
rate
nausea
sign
singledos
trial
increas
observ
cumul
rate
repeatdos
trial
anim
identifi
observ
pm
observ
cycl
examin
dorsal
skin
surfac
paw
actual
rate
trial
may
higher
anim
remov
studi
pm
observ
rate
increas
trial
increas
dose
drug
trial
behavior
selflimit
produc
appar
last
consequ
incid
similar
incid
nausearel
behavior
report
human
patient
treat
opiat
therapi
weight
loss
cite
deterr
use
postsurg
buprenorphin
analgesia
link
signific
morbid
secondari
gastrointestin
blockag
associ
hardwood
bed
number
report
describ
weight
loss
rat
treat
buprenorphin
without
refer
bed
use
experi
report
use
hardwood
bed
without
refer
previou
report
associ
hardwood
bed
pica
previou
studi
demonstr
risk
picarel
gastric
distress
control
appropri
choic
bed
studi
report
confirm
observ
appear
clinic
signific
treatmentrel
effect
follow
repeat
subcutan
inject
extend
releas
lipid
suspens
buprenorphin
mgkg
mgkg
mgkg
dose
although
sever
clinic
patholog
find
exceed
normal
limit
urinalysi
result
show
abnorm
paramet
correl
chang
find
bodi
weight
clinic
observ
organ
weight
microscop
evalu
tissu
guarnieri
own
signific
financi
interest
animalges
lab
author
declar
conflict
interest
